* SI International, a Reston government contractor, said it earned $2.7 million (30 cents a share) during the second quarter ended June 26, up 69 percent from a $1.6 million (19 cents) profit in the same period last year. The company's second-quarter revenue rose 57 percent to $63.8 million from $40.7 million in the comparable 2003 period. Revenue from federal agencies, which makes up 97 percent of SI's business, increased 62 percent year-to-year. For the first six months of the year, SI earned $5 million (56 cents) on $119.8 million in revenue, 61 percent more than its $3.1 million (37 cents) profit on $82 million in revenue during 2003's first half. Shares of SI closed at $18.65, down 11 cents.

* The Corporate Executive Board, a Washington provider of corporate research and analysis, earned $12.7 million (32 cents a share) in the second quarter ended June 30, up 34 percent from $9.5 million (25 cents) during the same period last year. Revenue rose 34 percent, to $67.2 million from $50.3 million a year ago. For the first six months, the company earned $24.7 million (63 cents) on $131.2 million in revenue, 39 percent more than its 2003 first-half profit of $17.8 million (47 cents) on $97.6 million in revenue. Shares of the company closed at $52.44, down 86 cents.

* Intersections, a Chantilly company that provides identity theft protection and credit management services, earned $2.9 million (17 cents a share) in the second quarter ended June 30, down 29 percent from $4.1 million (29 cents) during the comparable 2003 period. Revenue rose 7 percent year-to-year to $40.2 million from $37.5 million. For the first six months, the company earned $5.1 million (33 cents) on $78.4 million in revenue, 31 percent less than its 2003 first-half profit of $7.4 million (53 cents) on $72.7 million in revenue. Shares closed at $20.06, down 22 cents.

* MedImmune, a Gaithersburg pharmaceutical company, said the Food and Drug Administration has approved a new liquid formulation of Synagis, a treatment for infant lung infections. MedImmune plans to end production of the original freeze-dried formulation for the United States and begin manufacturing the liquid Synagis, which should be available in 2005. Shares closed unchanged at $22.51.

* SRA International, a Fairfax government information technology services provider, has been awarded a five-year contract worth up to $19.9 million by the Defense Advanced Research Projects Agency (DARPA) to provide technical and program support to its Tactical Technology Office.

Compiled from reports by Washington Post staff writers.